MacroGenics, Inc. (MGNX)Healthcare | Biotechnology | Rockville, United States | NasdaqGS
3.28 USD
-0.09
(-2.819%) ⇩
(Oct. 16, 2026, 2:56 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:07 a.m. EDT
The investment case for MacroGenics is currently broken by a perfect storm of deteriorating fundamentals and overwhelming speculative fear. The company is trapped in a multi-year structural decline, having lost over 94% of its value since 2016, with the last two years seeing double-digit percentage drops. While the balance sheet remains technically solvent with minimal debt, the business is bleeding cash, posting negative operating margins, and failing to generate free cash flow. The recent news of slipping trial data for its lead asset confirms the market's skepticism regarding its pipeline's ability to deliver value soon enough to justify the current valuation. The short-term outlook is bleak, driven by a stark divergence between analyst optimism and actual market mechanics. While analysts see a path to an $8 price target, the options market tells a different story: traders are aggressively buying puts, creating a heavy wall of resistance that suggests they expect the stock to fall further, not recover. With a short ratio of 16x, the stock is heavily shorted, meaning any bad news could trigger a short squeeze, but the current momentum is firmly downward. Without a miraculous clinical success or a major strategic acquisition, the trajectory points toward continued erosion of shareholder value. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.039234 |
| AutoETS | 0.064421 |
| MSTL | 0.067806 |
| AutoTheta | 0.068609 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 29.80 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.020 |
| Excess Kurtosis | 0.35 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 81.851 |
| Revenue per Share | 2.763 |
| Market Cap | 208,618,128 |
| Forward P/E | -2.23 |
| Beta | 1.21 |
| Profit Margins | -8.33% |
| Website | https://www.macrogenics.com |
As of Oct. 10, 2026, 10:07 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across all expirations, with deep out-of-the-money puts showing massive volume relative to their open interest (e.g., 60 volume vs 63 OI for the April 3-strike put). This indicates a 'bear put spread' or hedging strategy where traders are betting on further declines or insuring existing long positions against a crash, rather than anticipating a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0424242 |
| Address1 | 9,704 Medical Center Drive |
| All Time High | 41.0 |
| All Time Low | 0.99 |
| Ask | 4.16 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 624,450 |
| Average Daily Volume3 Month | 593,357 |
| Average Volume | 593,357 |
| Average Volume10Days | 624,450 |
| Beta | 1.205 |
| Bid | 2.4 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 0.674 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.275 |
| Current Ratio | 2.956 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.45 |
| Day Low | 3.245 |
| Debt To Equity | 81.851 |
| Display Name | MacroGenics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,742,502,600 |
| Earnings Call Timestamp Start | 1,742,502,600 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -32,169,000 |
| Ebitda Margins | -0.18367 |
| Enterprise To Ebitda | -2.377 |
| Enterprise To Revenue | 0.437 |
| Enterprise Value | 76,456,632 |
| Eps Forward | -1.4656 |
| Eps Trailing Twelve Months | -1.7 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 301 251 5321 |
| Fifty Day Average | 3.9562 |
| Fifty Day Average Change | -0.6811998 |
| Fifty Day Average Change Percent | -0.17218538 |
| Fifty Two Week Change Percent | 104.24242 |
| Fifty Two Week High | 5.08 |
| Fifty Two Week High Change | -1.8049998 |
| Fifty Two Week High Change Percent | -0.35531494 |
| Fifty Two Week Low | 1.29 |
| Fifty Two Week Low Change | 1.9850001 |
| Fifty Two Week Low Change Percent | 1.5387598 |
| Fifty Two Week Range | 1.29 - 5.08 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,381,411,800,000 |
| Float Shares | 56,407,153 |
| Forward Eps | -1.4656 |
| Forward P E | -2.2345798 |
| Free Cashflow | -69,411,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 293 |
| Fullday Change | -0.09499979 |
| Fullday Change Percent | -2.818985 |
| Fullday Price | 3.275 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -0.00745 |
| Gross Profits | -1,304,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03494 |
| Held Percent Institutions | 0.76445 |
| Implied Shares Outstanding | 63,700,187 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland. |
| Long Name | MacroGenics, Inc. |
| Market | us_market |
| Market Cap | 208,618,128 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_600911 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -101,056,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 242,697,712 |
| Number Of Analyst Opinions | 4 |
| Open | 3.45 |
| Operating Cashflow | -63,724,000 |
| Operating Margins | -0.42191002 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 301 251 5172 |
| Previous Close | 3.37 |
| Price Hint | 4 |
| Price To Book | 4.8590503 |
| Price To Sales Trailing12 Months | 1.1911371 |
| Profit Margins | -0.08332 |
| Quick Ratio | 2.918 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.09499979 |
| Regular Market Change Percent | -2.818985 |
| Regular Market Day High | 3.45 |
| Regular Market Day Low | 3.245 |
| Regular Market Day Range | 3.245 - 3.45 |
| Regular Market Open | 3.45 |
| Regular Market Previous Close | 3.37 |
| Regular Market Price | 3.275 |
| Regular Market Time | 1,792,176,983 |
| Regular Market Volume | 233,722 |
| Return On Assets | -0.080520004 |
| Return On Equity | -2.25846 |
| Revenue Growth | 3.78 |
| Revenue Per Share | 2.763 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 63,700,187 |
| Shares Percent Shares Out | 0.1105 |
| Shares Short | 7,039,348 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 7,124,937 |
| Short Name | MacroGenics, Inc. |
| Short Percent Of Float | 0.1145 |
| Short Ratio | 12.63 |
| Source Interval | 15 |
| State | MD |
| Symbol | MGNX |
| Target High Price | 11.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 8.0 |
| Target Median Price | 8.5 |
| Total Cash | 173,304,992 |
| Total Cash Per Share | 2.721 |
| Total Debt | 35,092,000 |
| Total Revenue | 175,142,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.3551 |
| Two Hundred Day Average Change | -0.08009982 |
| Two Hundred Day Average Change Percent | -0.02387405 |
| Type Disp | Equity |
| Volume | 233,722 |
| Website | https://www.macrogenics.com |
| Zip | 20,850 |